Korro Bio, Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 M

 

• Korro will be focused on advancing a wholly owned portfolio of RNA editing programs
• Post-transaction cash of approximately $170 million expected to fund operations into 2026
• Funds multiple potentially value-creating milestones, including advancing its lead product candidate in Alpha-1 antitrypsin deficiency (AATD) through a clinical trial
• Shares to trade on Nasdaq under the ticker “KRRO” commencing on November 6, 2023

https://www.globenewswire.com/news-release/2023/11/03/2773416/0/en/UPDATE-Korro-Bio-and-Frequency-Therapeutics-Announce-Closing-of-Merger-and-Private-Placement-of-117-Million.html